Bond.az reports: Gilead Sciences' Trodelvy has received a positive opinion from the European Medicines Agency's committee for use as a first-line treatment in triple-negative breast cancer. The recommendation is based on the Phase 3 ASCENT-03 study, which showed a 38% reduction in disease progression or death risk.
The European Commission decision is expected later in 2026. Trodelvy is already approved in over 60 countries for later-line treatments.
Triple-negative breast cancer accounts for 15% of all breast cancers and is the most aggressive type, with a 12% five-year survival rate for metastatic cases.
Gilead has also filed for FDA approval based on ASCENT-03 and for a combination with Keytruda. Over 75,000 patients have been treated with Trodelvy since 2020.
According to Bond.az analysis, Gilead appears undervalued at current levels.
